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Abstract
A Web-based statistical tool for sample size and power estimation in animal
carcinogenicity studies is presented in this paper. It can be used to provide a design
with sufficient power for detecting a dose-related trend in the occurrence of a tumor
of interest when competing risks are present. The tumors of interest typically are
occult tumors for which the time to tumor onset is not directly observable. It is ap-
plicable to rodent tumorigenicity assays that have either a single terminal sacrifice
or multiple (interval) sacrifices. The design is achieved by varying sample size per
group, number of sacrifices, number of sacrificed animals at each interval, if any,
and scheduled time points for sacrifice. Monte Carlo simulation is carried out in this
tool to simulate experiments of rodent bioassays because no closed-form solution is
available. It takes design parameters for sample size and power estimation as inputs
through the World Wide Web. The core program is written in C and executed in
the background. It communicates with the Web front end via a Component Object
Model interface passing an Extensible Markup Language string. The proposed sta-
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tistical tool is illustrated with an animal study in lung cancer prevention research.
Key Words: Competing risks; Experimental design; Monte Carlo simulation; Mul-
tiple/Single Sacrifice.
1 Introduction
Due to easy accessibility, the World Wide Web (WWW) provides an excellent environ-
ment for deploying statistical tools. One major advantage to the users is that statistical
design and analysis can be performed at any place where an Internet connection is avail-
able. It does not require that a user acquire, download, or purchase a statistical software
to run a program. The technology for the WWW interface has been developed and
applied to various statistical applications (to name a few: Banfield, 1999; Firth, 2000;
West and Ogden, 1997).
A Web-based sample size and power estimator using Monte Carlo simulation is pro-
posed in this paper. This statistical tool is designed for animal carcinogenicity/tumorigenicity
studies on occult tumors, and for rodent bioassays with a single terminal sacrifice or
multiple (interval) sacrifices. The estimator takes inputs from the WWW through an
Extensible Markup Language (XML) interface and simulates the specified design in the
background. The design input parameters include (a) number of dose groups, (b) type
of experiments with the number of interval sacrifices, (c) dose metric in each group,
(d) sample size per group, (e) time points for sacrifice, (f) number of sacrificed animals
at each interval, (g) tumor onset probability in the control group, (h) shape of tumor
onset distribution, (i) hazard ratio between each dose group and the control group, (j)
competing risks survival rate in each group, (k) parameter to determine lethality rate
in the control group, (l) significance level of a one- or two-sided test, and (m) number
of simulation runs. This tool sends results back to the user via e-mail. The results
include summary statistics, such as the simulated average tumor onset probability in
each group, the simulated average competing risks survival rate per group, the simulated
average tumor lethality rate in each group, along with the design considerations, and
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the estimated power. In this study, the core simulation program is written in C.
Animal carcinogenicity bioassays are routinely used to evaluate the carcinogenic
potential of chemical substances to which humans are exposed. In a typical animal
carcinogenicity study on occult tumors, each animal is assumed to begin with a tumor
free state. Mice or rats are commonly used species. They are randomized into a
control group (typically, animals that are exposed to a control agent or observed without
any exposure) or into 2 to 3 test groups that receive specified levels of exposure and
are observed until they either die or are sacrificed. In an experiment with multiple
sacrifices, sacrificed animals are pre-assigned to a specific dose level and sacrifice time
at the beginning of the experiment. In a single terminal sacrifice, all surviving animals
are sacrificed and subjected to necropsy at the end of the experiment, which is typically
a period of 104 weeks (2 years). During the study, age at death and the information
on the presence or absence of the tumor of interest are collected for each animal. The
primary goal of the experiment is to assess a dose-related trend of test agent exposures in
the incidence of the tumor of interest. The tumor of interest can be any occult tumor for
which the time to tumor onset is not directly observable. Our software can also seek a
reduced design (78 - 104 weeks) with an acceptable power. The proposed statistical tool
can also be used to seek an optimal design by choosing the design with the maximum
power of the trend test for a given total sample size. This tool will help researchers
conduct more efficient and cost effective experiments.
The logrank test of Mantel and Haenszel (1959) may be used for comparing hazards
of death from rapidly lethal tumors. To compare the prevalence of nonlethal tumors,
the prevalence test proposed by Hoel and Walburg (1972) may be used for incidental
tumors. However, the data obtained from a carcinogenicity experiment generally contain
a combination of fatal and incidental tumors. Peto et al. (1980) suggested combining
the fatal and incidental tests for comparing tumor onset distributions. The procedure
proposed by Peto et al., has been called the cause-of-death test or the Peto test.
The development of the presented statistical tool is motivated by a series of animal
studies at M. D. Anderson Cancer Center that explores the mechanisms underlying the
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chemopreventive effects of test agents. The first step is to establish the carcinogenic
potential of the tobacco carcinogen NNK, a byproduct of tobacco smoke, in retinoic acid
receptor-β (RAR-β) transgenic mice. The Peto test, recommended by the International
Agency for Research on Cancer (IARC), is used to compare the tumor incidence rate
among groups in the presence of potential confounders. It is a widely used statistical
test to determine a dose-related trend for a test agent in the occurrence of occult tumors.
The purpose of this paper is to present a statistical tool for Web-based sample size
and power estimation using the Peto test statistic to provide sufficient power for detecting
a dose-related trend in the occurrence of a tumor of interest. This package simulates
rodent bioassay experiments with either a single sacrifice or multiple sacrifices. A
comprehensive list of design parameters can be specified by the users through the WWW.
The underlying models are described in Section 2. A detailed description of the use
of the proposed estimator is demonstrated in Section 3. A design of a carcinogenesis
experiment for lung cancer prevention research is illustrated in Section 4 as an example.
Concluding remarks and suggested future study directions are described in the last
section.
2 Model and Test for a Sample Size and Power Estima-
tor
Consider a carcinogenicity/tumorigenicityexperiment with the control group and G −1
dose groups of animals. Suppose that Ni animals are randomly assigned to the i -th
group, and they are followed over time for the development of irreversible and occult
tumors. The animals in the i -th group receive a dose level of `i of a test agent. We
assume that all animals come from the same population and have no tumor on day zero
of the experiment. The time scale is divided into J intervals such that the j -th interval
is given by I j = (t j−1, t j ], j = 1, . . . , J . Note that t0 = 0 and t j denotes sacrifice
time point for j = 1, . . . , J . For an experiment with either a single sacrifice or multiple
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sacrifices, tJ denotes the terminal sacrifice time point.
It is assumed that three independent random variables completely determine the
observed outcome for each animal. The random variables are the time to onset of
tumor, T1; the time after onset until death from the tumor, T2; and the time to death
from competing risks, TC . Also let T1 + T2 = TD, where TD represents the overall
time to death from the tumor of interest. Thus the tumor of interest is present in an
animal at the time of death if T1 ≤ min{TC , TS}, where TS denotes a scheduled time
to sacrifice of an animal. When TD ≤ min{TC , TS}, an animal dies from the tumor of
interest. Otherwise, it dies from competing risks or sacrifice.
2.1 Distribution of the Random Variables
• Time to tumor onset (T1)
Let Si (t) be a survival function of the i -th group with respect to a random variable
T1 representing time to onset of the tumor of interest. Assume Si (t) follows a Weibull





where δ1 ≥ 0, δ2 ≥ 0, and tmax represents the duration of the study or the time for a
terminal sacrifice. The hazard ratio θi between the i -th dose group and the control group
(i = 1) is typically greater than or equal to 1 (θi = 1 for i = 1 and θi > 1 for i > 1) for
i = 1, . . . ,G. The scale parameter δ1 can be calculated by specifying the tumor onset
probability 1 − S1(tmax) at the end of the study in the control group. With θ1 = 1 and a
given shape parameter δ2, δ1 = − log S1(tmax). In this estimator, we allow the value of
the parameter δ2 of the Weibull distribution for ranging between 1.0 and 6.0 in order to
reflect a wide variety of tumor onset distributions. When there are no competing risks,
the tumor onset probability at the end of the study in each dose group is determined by
the hazard ratio and the baseline tumor onset probability in the control group by the end
of the study.
• Time to death from competing risks (TC )
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The survival function for time to death from competing risks, TC , is taken to be





where φi ≥ 1, γ1 ≥ 0, γ2 ≥ 0 and γ3 ≥ 0 (Portier et al., 1986). With φ1 = 1 in the






under the constraint that Q1(tmax) < exp(−γ1tmax), where Q1(tmax) is the probability
of survival with respect to competing risks in the control group at the end of the study.
The values of γ1 and γ2 are chosen as 10−4 and 10−16, respectively. These values are
close to the ones fitted to the historical control data such as Fisher 344 rats and B6C3F1
mice in Portier et al. (1986). These parameter values can be also found in many other
settings (Kodell and Ahn, 1996, 1997; Kodell et al., 1997; Ahn, Zhu and Yang, 1998;
Ahn et al., 2002). The competing risks survival rate can be determined according to
tumor types and historical data showing the survival rates of mice and rats. The value
of φi can be calculated after specifying the competing risks survival rate Q i(tmax) in (2)
such that φi = log [Qi(tmax)] / log[Q1(tmax)].
• Time to tumor death (T2)
For simplicity, the survival distribution for tumor-induced mortality, T2, is taken to
have the same form as that for death from competing risks
Fi (t) = exp
[
−ψi (γ1t + γ2tγ3)
]
, (3)
and the values of γ1, γ2 and γ3 remain the same as in (2). These types of models
using a modified Weibull distribution can be found in other literature (Kodell, Chen
and Moore, 1994; Ahn and Kodell, 1995; Kodell and Ahn, 1997). The parameter ψ1 is
selected by the user to reflect various tumor lethalities from low tumor lethality (where
approximately 5% of observed tumors are the cause of death) to high tumor lethality
(where approximately 60% or higher of observed tumors are the cause of death) in the
control group. We also assume that once the tumor is developed, the distribution of
time to death (T2) is the same in all dose groups. Therefore, ψi = φ1 for all i . The
lethality parameter indicates how the presence of a tumor of interest affects survival. A
highly lethal tumor could lead to death shortly after its onset. Less restrictive choices
for the distribution of T2 can also be considered.
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2.2 Construction of the Peto Test
The data are generated according to the distributions of T1, T2 and TC for each animal.
They are collected at the j -th interval according to the following five events: animals
died from the tumor of interest (d j ), animals died from competing risks while having
the tumor of interest (a1 j ), animals died without tumor (b1 j ), animals sacrificed with
tumor (a2 j ), and animals sacrificed without tumor (b2 j ). An animal dies from the tumor
of interest in the j -th interval if TD ∈ I j and TC > TD. An animal dies from other
causes with the tumor of interest in the j -th interval if TD > TC , T1 ≤ TC , and TC ∈ I j .
On the other hand, an animal dies without the tumor of interest in the j -th interval if
TC ∈ I j and T1 > TC . A sacrificed animal has the tumor of interest at the time of
sacrifice (t j ) if T1 ≤ t j , TD > t j , and TC > t j . It does not have the tumor at the time of
sacrifice when T1 > t j and TC > t j . These data are applied to the Peto test to estimate
sample size and power.
First, consider the animals that did not have the specific tumor before death or
tumor-bearing animals for which that tumor was not the cause of death. Let n i j =
a1i j + a2i j + b1i j + b2i j be the number of animals in group i dying during interval I j
from causes unrelated to the presence of the tumor of interest, and let yi j = a1i j +a2i j be
the number of these animals in which the tumor was observed in the incidental context,
for i = 1, . . . ,G and j = 1, . . . , J . For each interval I j , the tumor prevalence data may
be summarized in a 2×G table, as in Table 1. All tumors found in sacrificed animals are
classified as incidental. The intervals defined by the pre-assigned NTP intervals (Bailer
and Portier, 1988) are recommended to implement the incidental part of the Peto test.
The expected number of tumors in the i -th group for the j-th interval is E i j = y. j Ki j ,
where Ki j = ni j /n. j . Thus, the observed and expected numbers of tumors in the i -th
group over the entire experiment are Oi =
∑J
j=1 yi j and Ei =
∑J
j=1 Ei j , respectively,
for i = 1, . . . ,G. Define










κ j Kr j (δri − Ki j ),
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Table 1: Tumor prevalence data for incidental tumors in interval I j
Dose group
1 2 · · · G Total
# with tumors y1 j y2 j · · · yG j y. j
# without tumors n1 j − y1 j n2 j − y2 j · · · nG j − yG j n. j − y. j
# deaths n1 j n2 j · · · nG j n. j
Table 2: Tumor mortality data for interval I j
Dose group
1 2 · · · G Total
# fatal tumor deaths in I j x1 j x2 j · · · xG j x. j
m1 j − x1 j m2 j − x2 j · · · mG j − xG j m. j − x. j
# surviving in I j m1 j m2 j · · · mG j m. j
where κ j = y. j (n. j − y. j )/(n. j − 1), and δri is defined as 1 if r = i and 0 otherwise.
Let Da = (D1, . . . , DG)T , and Va be the G × G matrix with (r, i ) entry Vri .
Second, consider the animals that died with a tumor of interest. The method used for
the fatal tumors is similar to that used for the incidental tumors. Table 2 is a contingency
table for tumor mortality data in the j -th interval. Data-determined intervals defined by
the actual death time of an animal were used for the fatal tumor analysis. Let m i j be the
number of animals in group i surviving at the beginning of the interval, and x i j = di j
be the number of these animals dying from the tumor of interest in that interval. A
vector Db that has the differences of observed and expected values using the data in
Table 2 is calculated in the same way as for the incidental tumors, and the corresponding
covariance matrix Vb is computed.
The analysis of data on occult tumors using contexts of observation is based on the
vector D = Da + Db, with covariance matrix V = Va + Vb. Then a dose-related trend
test can be considered by using
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Z R = lT D/
√
lT V l,
where l = (`1, . . . , `G)T , and `i stands for the dose metric for the i -th group with
0 = `1 < `2 < . . . < `G . Under the null hypothesis, Z R is asymptotically distributed
as a standard normal.
3 Usage of Sample Size and Power Estimator
The proposed estimator for sample size and power takes input parameters from a series
of pages in the Web site (http://biostatistics.mdanderson.org/ACSS). The title page in
Figure 1 provides a general description of the proposed estimator. By clicking the
Continue button, it moves to a user log-in and registration page, as shown in Figure 2.
A new user is required to register to obtain a user name and a password.
Users may save or retrieve their work by entering or selecting a file name. For a test
run, the session may remain as “default”, as shown in Figure 3. A default session name
automatically generated by concatenating the user name, date and time is provided, and
it shall be used as the “subject” of an e-mail for delivering the output. The session
name may be changed as the user wishes. Figure 4 shows a page of the detailed input
parameters in an experimental design. It starts with requesting three input parameters
(a) the number of dose groups, (b) whether the experiment uses multiple sacrifices or
a single terminal sacrifice, and (c) an integer seed for the random number generator.
The number of dose (or treatment) groups commonly considered are 2 to 4 groups,
including the control group. An experiment with multiple sacrifices is simulated to
perform sacrifices at specified interim time points, as well as a terminal sacrifice at
the end of the study. All the remaining live animals are assumed to be sacrificed at
the end of the experiment. The number of scheduled sacrifices, including the terminal
sacrifice, is typically either 3 or 4 in a two-year study. In addition, a seed for the random
number generator can be chosen by the user as any positive integer for the Monte Carlo
simulation.
Figure 5 shows other detailed input parameters, which are (a) dose metric in each
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Figure 1: A general description of the proposed estimator
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Figure 2: A user log-in page
Figure 3: The first input page
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Figure 4: Input parameters on the sample size and power estimation
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group, (b) sample size per group, (c) sacrifice time points, (d) number of sacrificed
animals at the end of each time interval, (e) tumor onset probability in the control group,
(f) shape parameter of the Weibull distribution for time to tumor onset, (g) hazard ratio
between each dose group and the control group, (h) competing risks survival rate per
group, (i) tumor lethality rate (low, intermediate, and high), (j) value of the lethality
parameter to determine a lethality rate in the control group, (k) significance level of one-
or two-sided test, and (l) number of simulation runs. Typically, animal carcinogenicity
studies on occult tumors are conducted in a duration of 104 weeks. This statistical tool
can also seek an efficient reduced design (78 - 104 weeks) with an acceptable power.
The default values are shown in Figures 3 - 5 for a typical two-year bioassay experiment
that has multiple sacrifices. For a design with 4 groups, the dose levels may be set
as a relative dose metric of 0, 1, 2 and 3 or 0, 1, 2 and 4 with respect to the control
and 3 dose groups. Alternatively, the actual dose levels may be used in a design. In a
typical two-year animal carcinogenicity study on occult tumors, 50 or more animals are
considered in a group. However, a different number of animals per group may be used
in a design. One needs to specify the time points of sacrifices in weeks. For a two-year
study, NTP intervals are, for example, 0 - 52, 53 - 78, 79 - 92, and 93 - 104 weeks. For
analyzing single-sacrifice data with the Peto test (described in Section 2), NTP intervals
were used for the incidental tumors. The NTP intervals for a two-year study are given
as a default. The number of sacrificed animals is decided at the beginning of a study.
Either the same number of sacrificed animals or a different number of animals can be
specified in each group and/or each interval.
The probability of tumor onset by the end of the study in the control group needs to be
specified in a design to determine the time to tumor onset. A tumor onset probability of
each dose group, therefore, is determined by a hazard ratio and a tumor onset probability
in the control group. An underlying distribution of time to tumor onset is assumed to
be a Weibull distribution (Kodell and Ahn, 1997). The shape parameter in the Weibull
tumor onset distribution ranges between 1.0 (exponential distribution) and 6.0 in order
to reflect a wide variety of tumor onset distributions. The hazard ratio is a ratio of
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Figure 5: More input parameters on the sample size and power estimation
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hazard rates between a dose group and the control group. A user needs to specify G −1
hazard ratios, where G is the number of groups, in the estimation of sample size to have a
desirable degree of power to detect a specified hazard ratio. Intercurrent mortality refers
to all deaths not related to tumors of interest. The causes of intercurrent mortality are
referred to as competing risks. Since a specific type of tumor may occur in the presence
of competing risks, intercurrent mortality rates (competing risks survival/death rates)
are considered in our design. They may be the same or different across dose groups.
The lethality parameter needs to be set to govern the tumor lethality rate in the control
group. Three tumor lethality rates (low, intermediate and high) are considered in this
paper. Tumors of low lethality generally have rates below 10%. Tumors of intermediate
lethality are typically those with rates between 35% and 40%. The rates 60% and above
are considered as highly lethal. To facilitate the choice of a tumor lethality parameter,
reference table(s), depending on study duration, tumor onset probability and tumor
onset distribution, will be shown in a separate window by clicking the Help button in
the section describing the tumor lethality parameter illustrated in Figure 5. The table
entries are obtained from a database that stores the information of a wide range of
lethality rates by the duration of the study, tumor rate and tumor onset distribution.
The value of a lethality parameter, then, can be chosen from the reference tables. A
reference table is shown in Figure 6 as an example. Tables 3–5 contain parameter values
to reflect tumor lethality. These values are predetermined by a numerical method for
a simulation model similar to (1)–(3) in Section 2.1 because there is no a closed-form
solution to obtain the lethality parameter values.
The significance level of the test typically can be specified 1%, 5% or 10%. The
choice of a one- or two-sided test is also needed to estimate power. The number of data
sets (i.e., simulation runs) needs to be decided for the Monte Carlo simulation. In this
example, 5000 simulation runs are given as a default value. The e-mail address of the
user is required to receive simulated results via e-mail.
Before submitting input parameters, all design parameters are displayed once again
on the Web page for verification (See Figure 7). Once all the input parameters entered
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Figure 5: More input parameters on the sample size and power estimation (continued)
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Figure 6: Helpful guidelines for selecting the tumor lethality parameter
Figure 7: Input parameters considered
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Figure 7: Input parameters considered (continued)
are confirmed, they are submitted to the compiled C program for simulation runs.
When the simulation runs are completed, an output file is sent to the e-mail address
specified by the user. A simulation with 5000 runs typically takes about 5 minutes.
The output file contains design parameters, average tumor rate, average competing
risks survival rate, average lethality rate for each group, and average death rate with
information on tumors and sacrifices per dose group. At the end, the power to detect a
dose-related trend is shown. Figure 8 shows an image of the output file generated from
the above example.
4 Example: Testing the Carcinogenic Potential of NNK
in a Prevention Study for Lung Cancer
The development of this statistical tool was motivated by a recent lung cancer prevention
study developed at M. D. Anderson Cancer Center. One particular goal was to evalu-
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Figure 8: Contents of an output file
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Figure 8: Contents of an output file (continued)
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ate the carcinogenic potential of the tobacco carcinogen NNK, a byproduct of tobacco
smoke, on the incidence of lung adenomas and adenocarcinomas (occurring either spon-
taneously or following exposure to the tobacco carcinogen NNK) in transgenic mice
that express antisense retinoic acid receptor-β (RAR-β). A Web-based sample size and
power estimator was applied to provide sufficient power to detect a dose-related trend
of the occurrence of lung adenomas and adenocarcinomas. The estimation of sample
size and power was conducted by the Peto test (see Section 2).
The power computation is based on the following assumptions. One hundred anti-
sense RAR-β hemizygous (+/0) mice and one hundred antisense RAR-β homozygous
(+/+) mice will be obtained for the experiments. For each type of mice, fifty mice will
be randomized into a group that either receives or does not receive exposure to NNK.
To test the carcinogenic potential of NNK, a dose metric of 0 or 1 is used for the control
group or exposed group, respectively. Serial sacrifices are scheduled at weeks 39, 52,
65, and 78 (at the end of the study). The time to lung cancer development is assumed
to follow a Weibull distribution with the shape parameter 3. It is expected that 55% of
the antisense RAR-β hemizygous mice will develop a lung cancer by 78 weeks. On the
other hand, 86% of the antisense RAR-β homozygous mice are expected to develop a
lung cancer by 78 weeks. In this experimental design, 85% competing risks survival
rate is considered. The lung adenomas and adenocarcinomas are assumed to be highly
lethal. Five thousand simulation trials are run.
The statistical power (in %) under the one-sided 5% nominal significance level is
listed in Table 6. A hazard ratio between the treatment group and the control group in
each type of mice is chosen as 2.0, 2.5 and 3.0. Three different designs are considered.
One is to estimate power with 6 mice at each serial sacrifice (39, 52 and 65 weeks) in
a total of 50 mice per group. Another setting is to calculate power with 6 sacrifices at
52 weeks out of a total of 55 in the control group and with 3 sacrifices at 52 weeks out
of a total of 45 in the dose group. The other configuration is to estimate power with
a total of 30 mice per group and 3 mice per serial sacrifice at 39, 52 and 65 weeks.
The same competing risks survival rate (85% for the control and a dose group) and
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different competing risks survival rates (85% for the control, 50% for a dose group)
are considered in this example. Under the null hypothesis of no treatment effect on the
tumor of interest, it may still be reasonable to assume different competing risk rates
among different dose groups. For example, even though the carcinogen may have no
effect on the development of lung cancer, it may increase competing risks, such as the
development of a liver tumor or bladder tumor, etc, and, consequently, results in lower
competing risks survival rates in the dose groups. A lung cancer is typically considered
as highly lethal in humans. The median survival time is less than a year for stage III
and less than 6 months for stage IV non-small cell lung cancer (Ginsberg et al., 1993).
Lethality parameters of 1500 and 800 are selected in hemizygous and homozygous
mice, respectively, to reflect highly lethal tumors. Expected lethality corresponding to
these parameters is about 80% in this example.
With 50 hemizygous mice in each group and the same competing risks survival rate
between groups, 79.9% power was achieved to detect a hazard ratio of 2. However, the
power decreased slightly to 75.8% with different competing risks survival rates. On
the other hand, at least 80% power was achieved with 50 homozygous mice in each
group. With 30 mice in each group of hemizygous and homozygous mice, we had
less than 80% power to detect a hazard ratio of 2 in the presence of both the same and
different intercurrent mortalities. A better design, in this example, was achieved with
the control group of 6 mice for an interim sacrifice at 52 weeks out of 55 mice in total,
and with a treatment group of 3 mice for an interim sacrifice at 52 weeks out of 45
mice in total. In this design, 80% power was achieved to detect a hazard ratio of 2 or
higher among antisense RAR-β hemizygous and homozygous mice with the same and
different competing risks survival rates.
5 Discussion
We have developed, based on our knowledge, the first Web-based sample size and power
simulator for animal carcinogenicity studies to detect a dose-related trend in tumor
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incidence following exposure to a putative carcinogen. It is applicable for studies on
occult tumors for which the time to tumor onset is not directly observable. It was
designed for rodent bioassays that have either multiple sacrifices or a single terminal
sacrifice.
The Peto test (Peto et al., 1980) is used to compare the incidence rate of occult tumors
among groups in the presence of potential confounders. It requires data with cause-of-
death information determined by pathologists. Monte Carlo simulation is introduced in
this tool to simulate experiments of rodent bioassays because no closed-form solution
is available.
This package could be used to construct a design with a sufficient power to detect
specified hazard ratios by varying the sample size, number of sacrifices, time points
for sacrifice, and number of sacrificed animals at each sacrifice, if any, under the given
design considerations. As an example, the application of this tool was illustrated by an
animal experiment for lung cancer prevention research. An advantage of the proposed
Web-based sample size and power estimator is wider accessibility to the user, provided
that an Internet connection and a Web browser are available (Microsoft Internet Explorer
5.5 and above, or Netscape 4.76 and above). In addition, this statistical tool provides a
user-friendly environment so that the user can search for an optimal design.
Figure 9 shows a flowchart for the communication between the Web front end and
the core program. Input data are supplied to the proposed tool via a user-interface
implemented with Web pages. When the user presses the Submit button on the last Web
page, the user input is captured by the Web application and packaged into XML string
format (see packSimDataIntoXML.inc JavaScript file in Appendix A.1). Then,
it is sent to a queue implemented by a Perl module (see xprocessOutputR.asp
in Appendix A.2) for temporary storage until the time at which it can be scheduled
for processing by the calculation kernel program. Every few minutes a Queue Reader
process running on a separate compute-server machine scans the queue for waiting input
data. When new data is found, it is sent (still in XML format) to the calculation kernel
program. This returns the results to the Queue Reader. The Queue Reader then sends
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the results to the user via e-mail. This asynchronous “queued” architecture is chosen
so that multiple jobs requiring calculation times ranging from a few seconds to several
hours could be accommodated. The communication with the queue is done through a
custom software component implemented with Microsoft’s Component Object Model
(COM) technology. This allows the actual queue (a relational database) to be abstracted
from the remainder of the system, so that the queue can be changed/upgraded without
requiring additional maintenance on the rest of the system.
Figure 10 shows a communication data-flow diagram inside the ACSS calculation
program in Figure 9. Inside the executable the XML string is processed inProcessIOFunc
and ComposeStruct functions. The latter calls the XML parser from an external
XML Parsing Library and initializes the XMLInputStruct, which is passed as an
input parameter to the ACSSFunc function.
Through a Monte Carlo simulation study, the proposed tool can seek an efficient
design. For a given sample size and study duration, an optimal design can be obtained
using our tool by choosing the design with the maximum power of the trend test. This
tool can help investigators conduct more efficient and cost effective experiments.
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A.1 packSimDataIntoXML.inc JavaScript file
<%
// Pack the data for the current simulation into an XML string
function packSimDataIntoXML()
{
var xml = "<acss ";
xml += "numgroups = ‘x1’ ";
xml += "numsacrifices = ‘x2’ ";
xml += "studyduration = ‘x3’ " ;
xml += "tumoronsetprob = ‘x4’ ";
xml += "shapeparameter = ‘x5’ ";
xml += "lethalityrate = ‘x6’ ";
xml += "tumorlethalityparameter = ‘x7’ ";
xml += "numdatasets = ‘x8’ ";
xml += "testlevel = ‘x9’ ";
xml += "testsides = ‘k1’ ";
xml += "seed = ‘k2’ ";
xml += "multiplicity = ‘k3’ ";
xml += "sessionName = ‘k4’>";
xml = xml.replace(/x1/, Session("NumDoseGroups"));
xml = xml.replace(/x2/, Session("NumSacrifices"));
xml = xml.replace(/x3/, Session("StudyDuration"));
xml = xml.replace(/x4/, Session("TumorOnsetProb"));
xml = xml.replace(/x5/, Session("ShapeParameter"));
xml = xml.replace(/x6/, Session("LethalityRate"));
xml = xml.replace(/x7/, Session("TumorLethalityParameter"));
xml = xml.replace(/x8/, Session("NumDataSets"));
xml = xml.replace(/x9/, Session("TestLevel"));
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xml = xml.replace(/k1/, Session("TestSides"));
xml = xml.replace(/k2/, Session("FixedSeed"));
xml = xml.replace(/k3/, Session("Experiments"));
xml = xml.replace(/k4/, Session("sessionName"));
var i, temp, length;
var groupTemplate = "<group crsr=‘xx’ DoseMetric =‘zz’ num=‘yy’
NumPerGroup=‘ff’ />";
for (i = 0; i < Session("NumDoseGroups"); i++)
{
temp = groupTemplate.replace(/xx/, Session("crsr" + i));
temp = temp.replace(/zz/,Session("DoseMetric"+i));
temp = temp.replace(/ff/, Session("NumPerGroup"+i));
xml += temp.replace(/yy/, i);
}
var groupHazardTemplate = "<hazardgroup HazardRate =‘xx’ />";
for (i = 1; i < Session("NumDoseGroups"); i++)
{




var sacrificeTemplate = "<sacrifice SacrificeTimes=‘yy’ num=‘zz’/>";
for (i = 1; i <= Session("NumSacrifices")-1; i++)
{
temp = sacrificeTemplate.replace(/yy/, Session("SacrificeTimes"+i));
xml += temp.replace(/zz/, i);
}
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var interimSacrificesTemplate = "<interimsacrifices numInterimSacrifices
=‘xx’ />";
length = Session("NumDoseGroups")*(Session("NumSacrifices")-1);
for (i = 0; i < length ; i++)
{




















iMsgID = myQ.postMsg(iHandlerID, UserEmail, xmlInput);
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Table 3: Reference table for the parameter values for selecting low tumor lethality
(< 10%)
Weibull-1.0a Weibull-3.0 Weibull-6.0
Tumor Rate 78b 104 78 104 78 104
.05 2.50 2.00 25.0 20.0 50.0 40.0
.10 2.40 1.90 24.0 19.0 45.0 39.0
.15 2.30 1.80 23.0 18.0 43.0 38.0
.20 2.20 1.70 22.0 17.0 42.0 37.0
.25 2.10 1.60 21.0 16.0 41.0 36.5
.30 2.00 1.50 20.0 15.0 40.0 36.0
.35 1.90 1.40 19.0 14.0 39.5 35.5
.40 1.80 1.30 18.0 13.0 39.0 35.0
.45 1.70 1.20 17.0 12.0 38.5 34.5
.50 1.60 1.10 16.0 11.0 38.0 34.0
.55 1.50 1.05 15.0 10.5 37.5 33.4
.60 1.45 1.00 14.0 10.0 37.0 32.8
.65 1.40 0.95 13.0 9.5 36.0 32.2
.70 1.35 0.93 12.0 9.0 35.0 31.5
.75 1.30 0.90 11.0 8.7 34.0 30.5
.80 1.25 0.87 10.0 8.5 33.0 29.0
.85 1.20 0.84 9.0 8.3 32.0 27.0
.90 1.15 0.80 8.5 8.0 31.0 25.0
.95 1.10 0.70 8.0 7.5 30.0 23.0
aTumor onset distributions; bStudy duration in weeks
31
Table 4: Reference table for the parameter values for selecting intermediate tumor
lethality (≈ 40%)
Weibull-1.0a Weibull-3.0 Weibull-6.0
Tumor Rate 78b 104 78 104 78 104
.05 40.0 25.0 250.0 200.0 500.0 400.0
.10 39.0 24.0 240.0 190.0 450.0 390.0
.15 38.0 23.0 230.0 180.0 440.0 380.0
.20 37.0 22.0 220.0 170.0 435.0 370.0
.25 36.0 21.5 210.0 160.0 430.0 360.0
.30 35.0 21.0 200.0 150.0 425.0 350.0
.35 34.0 20.5 195.0 145.0 420.0 340.0
.40 31.0 20.0 192.0 143.0 415.0 330.0
.45 28.0 19.0 190.0 140.0 410.0 320.0
.50 26.0 18.0 186.0 137.0 405.0 310.0
.55 24.0 17.0 182.0 135.0 400.0 300.0
.60 22.0 16.0 178.0 132.0 390.0 285.0
.65 21.0 15.0 174.0 130.0 380.0 270.0
.70 20.0 14.0 170.0 127.0 370.0 260.0
.75 19.0 13.0 165.0 124.0 360.0 250.0
.80 18.0 11.0 160.0 120.0 340.0 240.0
.85 17.0 10.0 150.0 110.0 320.0 230.0
.90 13.0 8.0 130.0 100.0 300.0 220.0
.95 10.0 6.0 100.0 80.0 250.0 210.0
aTumor onset distributions; bStudy duration in weeks
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Table 5: Reference table for the parameter values for selecting high tumor lethality
(> 60%)
Weibull-1.0a Weibull-3.0 Weibull-6.0
Tumor Rate 78b 104 78 104 78 104
.05 300.0 250.0 2500.0 2000.0 4000.0 2800.0
.10 295.0 245.0 2400.0 1900.0 3500.0 2600.0
.15 290.0 240.0 2300.0 1800.0 3000.0 2400.0
.20 288.0 230.0 2200.0 1700.0 2800.0 2200.0
.25 285.0 220.0 2100.0 1600.0 2750.0 2100.0
.30 283.0 210.0 2000.0 1500.0 2700.0 2000.0
.35 280.0 200.0 1900.0 1400.0 2650.0 1900.0
.40 278.0 190.0 1800.0 1300.0 2600.0 1850.0
.45 275.0 180.0 1700.0 1200.0 2550.0 1800.0
.50 270.0 170.0 1600.0 1100.0 2500.0 1750.0
.55 265.0 160.0 1500.0 1000.0 2450.0 1700.0
.60 260.0 150.0 1400.0 900.0 2400.0 1650.0
.65 250.0 140.0 1300.0 800.0 2300.0 1600.0
.70 240.0 130.0 1200.0 700.0 2200.0 1550.0
.75 210.0 120.0 1100.0 650.0 2100.0 1500.0
.80 180.0 110.0 900.0 600.0 2000.0 1400.0
.85 150.0 100.0 800.0 550.0 1800.0 1200.0
.90 110.0 80.0 700.0 500.0 1600.0 1050.0
.95 70.0 60.0 600.0 400.0 1400.0 900.0
aTumor onset distributions; bStudy duration in weeks
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Table 6: Power calculation for animal carcinogenicity studies of NNK in Antisense
RAR-β mice
Type of mice CRSRa Hazard ratio (6,50)b (6,55,3,45)c (3,30)d
Antisense RAR-β 2.0 79.9 84.6 61.2
hemizygous (+/0) samee 2.5 95.4 97.4 84.4
mice 3.0 99.2 99.7 94.2
2.0 75.8 80.4 57.9
different f 2.5 94.0 96.0 81.8
3.0 98.9 99.5 92.8
Antisense RAR-β 2.0 84.8 87.8 66.1
homozygous (+/+) same 2.5 97.2 97.7 85.2
mice 3.0 99.3 99.7 93.6
2.0 82.8 84.7 63.5
different 2.5 96.4 96.8 83.6
3.0 99.2 99.4 93.0
aCompeting Risks Survival Rate
b6 mice at each serial sacrifice (39, 52, 65 weeks) and a total of 50 mice per group
c6 mice at an interim sacrifice (52 weeks) and a total of 55 mice (control group);
3 mice at an interim sacrifice (52 weeks) and a total of 45 mice (dose group)
d 3 mice at each serial sacrifice (39, 52, 65 weeks) and a total of 30 mice per group
e85% CRSR for the control and a dose group
f 85% CRSR for the control and 50% CRSR for a dose group
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Figure 9: A flowchart for the communication between the front end and the core program
35
Figure 10: A data-flow diagram inside ACSS calculation program in Figure 9.
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